Enterprise Value
128.5M
Cash
34.47M
Avg Qtr Burn
-7.178M
Short % of Float
1.32%
Insider Ownership
3.98%
Institutional Own.
45.91%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ciforadenant (A2AR inhibitor) Details Renal cell carcinoma, Cancer | Phase 2 Data readout | |
Mupadolimab (CPI-006) (Anti-CD73) Details Renal cell carcinoma, Lung cancer, Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Mupadolimab + pembrolizumab Details HPV+ oropharyngeal cancer, Head and neck cancer, Non-small cell lung carcinoma, Cancer | Phase 1b Data readout | |
CPI-818 (ITK inhibitor) Details Cutaneous T cell lymphoma, Lymphoma, Cancer, Blood cancer | Phase 1b Data readout | |
Failed Discontinued |